Palisade Bio announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer. Dr. Jones most recently served as Vice President of Corporate Development & Strategy at Chemomab Therapeutics, a Nasdaq-listed clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PALI:
- Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
- Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
- Palisade Bio announces $2M registered direct offering
- Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
- Palisade Bio enters licensing agreement with Giiant Pharma
